JP2015520170A5 - - Google Patents

Download PDF

Info

Publication number
JP2015520170A5
JP2015520170A5 JP2015514227A JP2015514227A JP2015520170A5 JP 2015520170 A5 JP2015520170 A5 JP 2015520170A5 JP 2015514227 A JP2015514227 A JP 2015514227A JP 2015514227 A JP2015514227 A JP 2015514227A JP 2015520170 A5 JP2015520170 A5 JP 2015520170A5
Authority
JP
Japan
Prior art keywords
metabolic syndrome
hsp90
hsp90 modulator
modulator according
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015514227A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015520170A (ja
JP6478908B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/042692 external-priority patent/WO2013177535A2/en
Publication of JP2015520170A publication Critical patent/JP2015520170A/ja
Publication of JP2015520170A5 publication Critical patent/JP2015520170A5/ja
Application granted granted Critical
Publication of JP6478908B2 publication Critical patent/JP6478908B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015514227A 2012-05-25 2013-05-24 熱ショックタンパク質（ＨＳＰ）９０−βを調節することによる代謝症候群の治療方法 Expired - Fee Related JP6478908B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261652023P 2012-05-25 2012-05-25
US61/652,023 2012-05-25
PCT/US2013/042692 WO2013177535A2 (en) 2012-05-25 2013-05-24 Methods of treating a metabolic syndrome by modulating heat shock protein (hsp) 90-beta

Publications (3)

Publication Number Publication Date
JP2015520170A JP2015520170A (ja) 2015-07-16
JP2015520170A5 true JP2015520170A5 (https=) 2016-07-14
JP6478908B2 JP6478908B2 (ja) 2019-03-06

Family

ID=49624539

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015514227A Expired - Fee Related JP6478908B2 (ja) 2012-05-25 2013-05-24 熱ショックタンパク質（ＨＳＰ）９０−βを調節することによる代謝症候群の治療方法

Country Status (15)

Country Link
US (2) US9533002B2 (https=)
EP (1) EP2854865B1 (https=)
JP (1) JP6478908B2 (https=)
KR (1) KR20150010793A (https=)
CN (1) CN104812898B (https=)
AU (1) AU2013266086B2 (https=)
BR (1) BR112014029301A2 (https=)
CA (1) CA2874676A1 (https=)
EA (1) EA201492184A1 (https=)
HK (1) HK1209035A1 (https=)
IL (1) IL235910A0 (https=)
MX (1) MX2014014188A (https=)
NZ (1) NZ702169A (https=)
SG (1) SG11201407775WA (https=)
WO (1) WO2013177535A2 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6478908B2 (ja) * 2012-05-25 2019-03-06 バーグ エルエルシー 熱ショックタンパク質（ＨＳＰ）９０−βを調節することによる代謝症候群の治療方法
RS58010B1 (sr) 2012-09-27 2019-02-28 Childrens Medical Ct Corp Jedinjenja za lečenje gojaznosti i postupci za njihovu upotrebu
CA3044998A1 (en) * 2014-03-26 2015-10-01 The Children's Medical Center Corporation Celastrol and derivatives for the treatment of obesity
WO2015188198A2 (en) * 2014-06-06 2015-12-10 Berg Llc Methods of treating a metabolic syndrome by modulating heat shock protein (hsp) 90-beta
JP6779867B2 (ja) * 2014-06-13 2020-11-04 ユマ セラピューティクス，インコーポレーテッド ピリミジン化合物およびその使用方法
WO2016149575A1 (en) * 2015-03-19 2016-09-22 Old Dominion University Synergistic regulated cell death induction with hsp90 inhibitors and nanosecond pulsed electric fields
JP7034078B2 (ja) * 2015-10-23 2022-03-11 イーアールエックス ファーマシューティカルズ インコーポレイテッド セラストロールの類似体
CN105920018B (zh) * 2016-06-15 2019-01-11 上海市内分泌代谢病研究所 雷公藤红素联合小檗碱制备治疗肥胖药物的用途
CN107543929A (zh) * 2016-06-23 2018-01-05 中国医学科学院肿瘤医院 基于蛋白标志物hsp90ab1诊断肺癌患者的试剂盒
CN107028953A (zh) * 2017-03-27 2017-08-11 北京大学 一种交感神经活性的刺激剂
KR20190138871A (ko) * 2017-04-24 2019-12-16 사무스 테라퓨틱스, 인코포레이티드 Hsp90 저해제 경구 제형 및 관련 방법
WO2018235251A1 (ja) 2017-06-23 2018-12-27 株式会社ニコン 解析装置、解析プログラム及び解析方法
CN112156188A (zh) * 2020-11-10 2021-01-01 上海交通大学医学院附属瑞金医院 Hsp90作为制备预防与治疗类固醇糖尿病药物的用途
CN113332308A (zh) * 2021-02-22 2021-09-03 广东省妇幼保健院 调控hsp90 b1表达量的制剂在制备预防或治疗多囊卵巢综合征药物中的应用
CN113160983A (zh) * 2021-04-09 2021-07-23 南京医科大学附属逸夫医院 一种代谢相关脂肪性肝病临床预测模型

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7078375B1 (en) 1996-10-25 2006-07-18 Peter Mose Larsen Diabetes-mediating proteins and therapeutic uses thereof
US20040048256A1 (en) * 2001-09-07 2004-03-11 Agee Michele L. Novel proteins and nucleic acids encoding same
EP1576124A2 (en) 2002-10-07 2005-09-21 Antigenics Inc. Heat shock protein binding fragments of cd91, and uses thereof
WO2004072080A1 (en) 2003-02-10 2004-08-26 Cellular Genomics, Inc. Certain 8-heteroaryl-6-phenyl-imidazo[1,2-a]pyrazines as modulators of hsp90 complex activity
GB0309637D0 (en) 2003-04-28 2003-06-04 Cancer Rec Tech Ltd Pyrazole compounds
NZ546044A (en) 2003-08-29 2009-09-25 Vernalis Cambridge Ltd Pyrimidothiophene compounds
US20070249540A1 (en) 2004-05-24 2007-10-25 Adonia Papathanassiu Methods for Inhibiting Proteasome and Heat Shock Protein 90
WO2006020269A2 (en) 2004-07-19 2006-02-23 University Of Rochester Biomarkers of neurodegenerative disease
US20060094682A1 (en) 2004-10-29 2006-05-04 Odyssey Thera, Inc. Kinase inhibitors for the treatment of diabetes and obesity
US9120774B2 (en) 2004-11-03 2015-09-01 University Of Kansas Novobiocin analogues having modified sugar moieties
FR2885904B1 (fr) 2005-05-19 2007-07-06 Aventis Pharma Sa Nouveaux derives du fluorene, compositions les contenant et utilisation
WO2007022042A2 (en) 2005-08-11 2007-02-22 Novartis Ag Combinations comrising a protein kinase inhibitor being a pyrimidylaminobξnzamide compound and a hsp90 inhibitor such as 17-aag
US20070207950A1 (en) 2005-12-21 2007-09-06 Duke University Methods and compositions for regulating HDAC6 activity
WO2007077042A1 (en) 2006-01-06 2007-07-12 Topotarget Switzerland Sa New method for the treatment of gout or pseudogout
US8658633B2 (en) 2006-02-16 2014-02-25 Massachusetts Eye And Ear Infirmary Methods and compositions for treating conditions of the eye
CA2645930A1 (en) 2006-03-17 2007-09-27 Crossbeta Biosciences B.V. Methods of binding of cross-beta structures by chaperones
KR20090019790A (ko) 2006-05-19 2009-02-25 더 스크립스 리서치 인스티튜트 단백질 미스폴딩의 치료
WO2007139955A2 (en) 2006-05-25 2007-12-06 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
CA2661436A1 (en) 2006-08-24 2008-02-28 Serenex, Inc. Isoquinoline, quinazoline and phthalazine derivatives
WO2008024974A1 (en) 2006-08-24 2008-02-28 Serenex, Inc. Pyrimidine and pyrazine derivatives
EP2073802A1 (en) 2006-10-12 2009-07-01 Astex Therapeutics Limited Pharmaceutical combinations
GB0620259D0 (en) * 2006-10-12 2006-11-22 Astex Therapeutics Ltd Pharmaceutical compounds
JP5518478B2 (ja) 2006-10-12 2014-06-11 アステックス、セラピューティックス、リミテッド 医薬化合物
GB0622084D0 (en) 2006-11-06 2006-12-13 Chroma Therapeutics Ltd Inhibitors of HSP90
BRPI0718562A2 (pt) 2006-11-09 2014-04-08 Biotica Tech Ltd Composto, processo para preparar e para gerar análogo de macbecina, análogo de macbecina, composição farmacêutica, uso do análogo de macbecina, e, cepa engenheirada.
EP2121957A4 (en) 2007-01-26 2010-11-10 Kosan Biosciences Inc MACROLACTAMES OBTAINED BY MODIFIED BIOSYNTHESIS
KR101313804B1 (ko) 2007-03-20 2013-10-01 쿠리스 인코퍼레이션 Ｈｓｐ９０ 억제제로서의 융합된 아미노 피리딘
GB2449293A (en) 2007-05-17 2008-11-19 Evotec Compounds having Hsp90 inhibitory activity
EP2164865A2 (en) 2007-06-13 2010-03-24 Hochschule Mannheim Compounds for the modulation of huntingtin aggregation, methods and means for identifying such compounds
IL184671A0 (en) 2007-07-17 2008-12-29 Hadasit Med Res Service Substances directed to heparanase c-terminal domain-or substance derived therefrom and uses thereof as modulators of heparanas biological activities
DE102007041116A1 (de) 2007-08-30 2009-03-05 Merck Patent Gmbh 1,3-Dihydro-isoindolderivate
TW200920357A (en) 2007-09-10 2009-05-16 Curis Inc HSP90 inhibitors containing a zinc binding moiety
EP2060565A1 (en) 2007-11-16 2009-05-20 4Sc Ag Novel bifunctional compounds which inhibit protein kinases and histone deacetylases
WO2009067245A2 (en) 2007-11-20 2009-05-28 University Of Florida Research Foundation, Inc. Compositions and methods for tissue repair
JP5582783B2 (ja) 2007-12-28 2014-09-03 武田薬品工業株式会社 細胞保護剤のスクリーニング方法
HRP20191953T8 (hr) 2008-03-07 2021-06-25 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. DERIVATI 1-BENZIL-3-HIDROKSIMETILINDAZOLA I NJIHOVA UPORABA U LIJEČENJU BOLESTI KOJE SE BAZIRAJU NA EKSPRESIJI MCP-1, CX3CR1 i P40
WO2009114470A2 (en) 2008-03-10 2009-09-17 Curis, Inc. Tetrahydroindole and tetrahdyroindazole as hsp90 inhibitors containing a zinc binding moiety
EP2100879A1 (en) 2008-03-13 2009-09-16 4Sc Ag Novel N-substituted tetrahydroisoquinoline/isoindoline hydroxamic acid compounds
BRPI0822354B1 (pt) 2008-05-19 2020-11-10 Hewlett Packard Development Company, L.P método para suportar login de pré-boot em sistemas de computador, mídia legível por computador e sistema de computador
JP5767965B2 (ja) * 2008-06-10 2015-08-26 プレキシコン インコーポレーテッドＰｌｅｘｘｉｋｏｎ Ｉｎｃ． キナーゼを調節する５ｈ−ピロロ［２，３−ｂ］ピラジン誘導体、およびその適応症
WO2010014617A1 (en) 2008-07-28 2010-02-04 University Of Kansas Heat shock protein 90 inhibitor dosing methods
CN102112481A (zh) 2008-08-04 2011-06-29 帝斯曼知识产权资产管理有限公司 使用过氧化氢或过酸由鼠尾草酸生产鼠尾草酚的方法
WO2010019965A1 (en) 2008-08-15 2010-02-18 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for modulating epsilon protein kinase c-mediated cytoprotection
WO2010030395A2 (en) 2008-09-15 2010-03-18 Whitehead Institute For Biomedical Research Withaferin a analogs and uses thereof
MA32934B1 (fr) 2008-11-28 2012-01-02 Novartis Ag Combinaisons inhibitrices hsp90
WO2010117425A1 (en) 2009-03-31 2010-10-14 Biogen Idec Ma Inc. Certain substituted pyrimidines, pharmaceutical compositions thereof, and methods for their use
WO2011083150A2 (en) * 2010-01-07 2011-07-14 Akron Molecules Gmbh Obesity small molecules
US20110201587A1 (en) * 2010-02-16 2011-08-18 Bio Holding, Inc. Hsp90 inhibitors and methods of use
JP2013519727A (ja) 2010-02-17 2013-05-30 イルドン ファーム シーオー．，エルティーディー． 新規の５員複素環誘導体及びその製造方法
CA2697887A1 (en) 2010-03-12 2011-09-12 Institut De Recherches Cliniques De Montreal Modulating and/or detecting activation induced deaminase and methods of use thereof
US9062072B2 (en) 2010-04-20 2015-06-23 Emory University Inhibitors of HIF and angiogenesis
WO2012106393A2 (en) 2011-02-01 2012-08-09 University Of Kansas Withanolide isolated from physalis longifolia and analogs and methods of use thereof
AU2012212323A1 (en) 2011-02-01 2013-09-12 The Board Of Trustees Of The University Of Illinois HDAC inhibitors and therapeutic methods using the same
US8685966B2 (en) 2011-04-08 2014-04-01 University Of Kansas GRP94 inhibitors
WO2013015661A2 (en) 2011-07-28 2013-01-31 Ildong Pharm Co.,Ltd. Novel prodrugs of 5-(2,4-dihydroxy-5-isopropylphenyl)-n-ethyl-4-(5-methyl1-1,2,4-oxadiazol-3-yl)isoxazole-3-carboxamide
JP6478908B2 (ja) * 2012-05-25 2019-03-06 バーグ エルエルシー 熱ショックタンパク質（ＨＳＰ）９０−βを調節することによる代謝症候群の治療方法
CN102772399A (zh) * 2012-08-16 2012-11-14 厦门大学 藤黄酸作为5`-amp激活的蛋白激酶激动剂的用途

Similar Documents

Publication Publication Date Title
JP2015520170A5 (https=)
Kalaki-Jouybari et al. High-intensity interval training (HIIT) alleviated NAFLD feature via miR-122 induction in liver of high-fat high-fructose diet induced diabetic rats
Bianco-Miotto et al. Epigenetics and DOHaD: from basics to birth and beyond
Cirillo et al. Obesity, insulin resistance, and colorectal cancer: could miRNA dysregulation play a role?
D’Souza et al. Acute resistance exercise modulates microRNA expression profiles: Combined tissue and circulatory targeted analyses
Scheler et al. Cytokine response of primary human myotubes in an in vitro exercise model
Roy et al. The role of miRNAs in the regulation of inflammatory processes during hepatofibrogenesis
Qiao et al. Expression of microRNA-122 and microRNA-22 in HBV-related liver cancer and the correlation with clinical features
Evers-van Gogh et al. Electric pulse stimulation of myotubes as an in vitro exercise model: cell-mediated and non-cell-mediated effects
Guo et al. Metformin-induced changes of the coding transcriptome and non-coding RNAs in the livers of non-alcoholic fatty liver disease mice
Satoh et al. A cellular microRNA, let-7i, is a novel biomarker for clinical outcome in patients with dilated cardiomyopathy
Pang et al. MiR-519d represses ovarian cancer cell proliferation and enhances cisplatin-mediated cytotoxicity in vitro by targeting XIAP
Panico et al. The influence of lifestyle factors on miRNA expression and signal pathways: a review
Banerjee et al. Role of microRNAs in type 2 diabetes and associated vascular complications
Wang et al. LncRNA-Ang362 promotes pulmonary arterial hypertension by regulating miR-221 and miR-222
Lundberg et al. Aerobic exercise augments muscle transcriptome profile of resistance exercise
Sung et al. Ulinastatin suppresses lipopolysaccharide-induced prostaglandin E2 synthesis and nitric oxide production through the downregulation of nuclear factor‑κB in BV2 mouse microglial cells
Ogata et al. Prolonged exercise training induces long-term enhancement of HSP70 expression in rat plantaris muscle
Ji et al. MicroRNA-327 regulates cardiac hypertrophy and fibrosis induced by pressure overload
Hernández-Aguilar et al. Dysregulation of lncRNA-H19 in cardiometabolic diseases and the molecular mechanism involved: a systematic review
Valášková et al. The severity of muscle performance deterioration in sarcopenia correlates with circulating muscle tissue-specific miRNAs
Nie et al. Analysis of non‑alcoholic fatty liver disease microRNA expression spectra in rat liver tissues
Wang et al. Chemokine CXCL14 acts as a potential genetic target for liver fibrosis
Li et al. Lactylation modification in cardiometabolic disorders: Function and mechanism
Han et al. Anti-inflammatory effects of prosapogenin III from the dried roots of Liriope platyphylla in LPS-stimulated RAW264. 7 cells